Measure Twice, Cut Once: Therapeutic Editing of HSPCs Requires Precise Planning

Cell Stem Cell. 2019 Apr 4;24(4):511-512. doi: 10.1016/j.stem.2019.03.001.


Hematologic diseases may be among the first clinical targets for therapeutic gene editing. In this issue of Cell Stem Cell, Schiroli et al. (2019) report a thorough, unbiased investigation of the impact of gene editing on hematopoietic stem and progenitor function and offer a clear path forward for editing in multiple tissues and conditions.

Publication types

  • Comment

MeSH terms

  • DNA Damage
  • Gene Editing*
  • Hematopoietic Stem Cells
  • Tumor Suppressor Protein p53*


  • Tumor Suppressor Protein p53